HTA130 Value Contribution of Olipudase Alfa Therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1588
https://www.valueinhealthjournal.com/article/S1098-3015(22)03793-7/fulltext
Title :
HTA130 Value Contribution of Olipudase Alfa Therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03793-7&doi=10.1016/j.jval.2022.09.1588
First page :
Section Title :
Open access? :
No
Section Order :
11139